Drugs / TIMCODAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00004030 | Mar 1996 → Jan 2001 | cancer of unknown primary site | Georgetown University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TIMCODAR | ChEMBL registry synonym — accepted as the source's own label CHEMBL2059028 ↗ |
| Known as | VX-853 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004030 ↗ |
| Modality | Small molecule | — CHEMBL2059028 ↗ |
| Route | Oral | “Patients receive VX-853 orally every 8 hours on days 1-3” NCT00004030 ↗ |